Therapy News and Research

RSS

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter and year-ended December 31, 2013.

25 Mar 2014

Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Spark Therapeutics and Genable Technologies announced today that they have entered into a collaboration agreement for Genable's lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO adRP), GT038.

25 Mar 2014

Radiation therapy fights cancer in more ways than one

Radiation therapy fights cancer in more ways than one. Not only does it force cancer cells to self-destruct, but several studies demonstrate that it also activates the immune system to attack tumor cells.

25 Mar 2014

Researchers develop mathematical model that provides insights about molecular mechanisms behind virus assembly

Mathematicians at the University of York have joined forces with experimentalists at the University of Leeds to take an important step in discovering how viruses make new copies of themselves during an infection.

25 Mar 2014

High-volume medical centers improve gynecologic cancer survival

Women with ovarian and other gynecologic cancers live significantly longer when they receive care at hospitals that treat a large number of patients with these conditions, according to research on more than 850,000 women.

25 Mar 2014

XBP1 gene plays pivotal role in the growth and progression of triple negative breast cancer

Scientists from Weill Cornell Medical College and Houston Methodist have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple negative form of the disease, a particularly deadly strain that often has few treatment options. Their research, published in this week's Nature, suggests that targeting the gene may be a new approach to treating the disease.

25 Mar 2014

$Fracture liaison services effective in identifying, treating older adults who suffer fragility fracture$

Fracture liaison services effective in identifying, treating older adults who suffer fragility fracture

Studies have shown that anyone age 50 or older who suffers a fragility fracture - a bone break sustained in a fall from a standing height or less - is two to five times more likely to experience a second fracture than someone who hasn't had one. The odds that a person who's suffered two such fractures will have a third are even higher.

25 Mar 2014

Marina Cavazzana, Adrian J. Thrasher honored with Pioneer Award for gene therapy

Marina Cavazzana, MD, PhD, Paris Descartes University, France and Adrian J. Thrasher, MD, PhD, University College London Institute of Child Health, UK, have been honored with the Pioneer Award for basic and clinical gene therapy for immunodeficiency disorders.

25 Mar 2014

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA.

25 Mar 2014

Treatment with natalizumab in patients with MS appears linked with JC virus infection

Treatment with natalizumab in patients with multiple sclerosis (MS) appears linked with JC virus (JCV) infection, which can lead to a rare and often fatal demyelinating disease of the central nervous system called progressive multifocal leukoencephalopathy (PML) that destroys the myelin that protects nerve cells.

25 Mar 2014

Antibiotics for UTI often taken before, after incontinence surgery

One in four women undergoing surgery for urinary incontinence has recently taken antibiotics for a urinary tract infection, a large population-based study shows.

24 Mar 2014

‘Residual risk’ concern for treated Japanese hypertension patients

Physicians should be alert to other sources of cardiovascular risk in patients with hypertension, even if they are receiving optimal antihypertensive treatment, say Japanese researchers.

24 Mar 2014

FDA approves Allure Quadra Cardiac Resynchronization Therapy Pacemaker

St. Jude Medical, Inc., a global medical device company, today announced approval from the U.S. Food and Drug Administration (FDA) for the Allure Quadra™ Cardiac Resynchronization Therapy Pacemaker (CRT-P), which provides additional pacing innovations for physicians to treat patients with heart failure.

24 Mar 2014

Anxiety relief in children: an interview with Dr. Golda Ginsburg, Johns Hopkins Children’s Center

Anxiety is the most common psychiatric disorder among youth. Prevalence rates hover around 10%, although the actual percent varies depending on the specific anxiety disorder, sample, method of assessment, etc.

24 Mar 2014

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Patrys Limited, a clinical stage biotechnology company, is pleased to provide an update on the development programme for anti-cancer product, PAT-LM1.

24 Mar 2014

Tuberculosis control needs a complete and patient-centric solution

Whether it is mobile phone service or vacation travel, good businesses know that success depends on providing a complete and customer-centric solution. Should patients with tuberculosis not be offered a complete solution that is patient-centered? After all, millions are affected and a large market at the base-of-the-pyramid (BoP) remains unserved.

24 Mar 2014

Drugs fail to "wake up" dormant reservoirs of HIV inside immune system T cells

Scientists at Johns Hopkins report that compounds they hoped would "wake up" dormant reservoirs of HIV inside immune system T cells - a strategy designed to reverse latency and make the cells vulnerable to destruction - have failed to do so in laboratory tests of such white blood cells taken directly from patients infected with HIV.

24 Mar 2014

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Medivir AB announced today that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.

24 Mar 2014

New insight into germline EGFR T790M mutation in familial non-small cell lung cancer

Two studies are providing new insight into germline epidermal growth factor receptor (EGFR) T790M mutation in familial non-small cell lung cancer (NSCLC). The findings suggest the need for tailored approaches for early detection and treatment, as well as for genetic testing to identify carriers.

24 Mar 2014

FDA approves Xolair for treatment of chronic idiopathic urticaria

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives.

24 Mar 2014

Therapy News and Research

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Radiation therapy fights cancer in more ways than one

Researchers develop mathematical model that provides insights about molecular mechanisms behind virus assembly

High-volume medical centers improve gynecologic cancer survival

XBP1 gene plays pivotal role in the growth and progression of triple negative breast cancer

Fracture liaison services effective in identifying, treating older adults who suffer fragility fracture

Marina Cavazzana, Adrian J. Thrasher honored with Pioneer Award for gene therapy

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

Treatment with natalizumab in patients with MS appears linked with JC virus infection

Antibiotics for UTI often taken before, after incontinence surgery

‘Residual risk’ concern for treated Japanese hypertension patients

FDA approves Allure Quadra Cardiac Resynchronization Therapy Pacemaker

Anxiety relief in children: an interview with Dr. Golda Ginsburg, Johns Hopkins Children’s Center

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Tuberculosis control needs a complete and patient-centric solution

Drugs fail to "wake up" dormant reservoirs of HIV inside immune system T cells

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

New insight into germline EGFR T790M mutation in familial non-small cell lung cancer

FDA approves Xolair for treatment of chronic idiopathic urticaria

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News